ArQule, Daiichi announce positive results from Phase 2 HCC study
The 107 patients, with unresectable HCC and had disease progression after first-line therapy or were unable to tolerate the first-line therapy, were randomized in the placebo-controlled, double-blinded study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.